American Journal of Infection Control

Since the emergence of COVID-19, the world has taken several measures to contain the spread of the disease. Immunization by vaccination has been one of the most important contributions to public health in the past century and is responsible for the

COVID-19 pneumonia is associated with a mortality up to 20% varying by country1 with the number of global deaths over 5 million.2 Antibiotics have been extensively used in COVID-19 patients in intensive care units (ICUs) without a clear indication.3

Traditionally, vaccine development is an extensive, long, and expensive process with no assurance of success despite the significant financial and human resources utilized.1 In past, vaccine development for epidemics - severe acute respiratory

My involvement in Veteran research began about 10-15 years ago through researchers at the Medical College of Wisconsin (MCW) and the Milwaukee VA. They were interested in Dryhootch of America, where I served as Cofounder and Director of Community

My comments are related to the original research entitled “Engaging Veterans in Identifying Key Elements of Environmental Cleaning and Disinfection for Preventing Healthcare-Associated Infections: A Qualitative Study.”

To assess trends in and factors associated with COVID-19 vaccination (≥ 1 dose) coverage, data from the Household Pulse Survey were analyzed. From April–August 2021, vaccination coverage with at least one dose increased from 70% to 82%, while

Infections of the lower respiratory tract are among the most common nosocomial infections in Intensive Care Units (ICU), contributing to increases in lengths of stay (LOS) and morbidity1. Moreover, the cost of care increases with the higher time of

Hospital surfaces in the vicinity of infected patients get contaminated by microbes shed by them, and eventually get colonized and transfer the microbes to other surfaces and humans they come in contact with.1 Survival and transmission of microbes to

Pfizer-BioNTech, Moderna, and Johnson & Johnson's Janssen are the three COVID-19 vaccines authorized for emergency use in the United States. This study aims to analyze and compare adverse events following immunization (AEFIs) associated with these

Globally, healthcare-associated infections (HAIs) remain a significant burden. Within the United States, approximately 687,200 HAIs are diagnosed in hospitalized patients annually, with deaths in 11% of these patients1. Additionally, the direct